⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30225167 | 0.97 | MEN1 (0.43) | — | |
| SCHEMBL22917058 | 0.81 | KMT2A (0.46) | — | |
| SCHEMBL18678083 | 0.80 | ALDH1A1 (0.40) | — | |
| SCHEMBL20371813 | 0.80 | — | — | |
| SCHEMBL9835275 | 0.79 | MEN1 (0.45) | — | |
| SCHEMBL24922966 | 0.78 | ACACB (0.34) | — | |
| SCHEMBL22822706 | 0.78 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL15123452 | 0.78 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL20748757 | 0.78 | ACACB (0.34) | — | |
| SCHEMBL25130123 | 0.78 | SMN1; SMN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086744-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024073610-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073436-A2 | COMPOSITIONS AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4265275-A1 | TROP2 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265274-A1 | B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023154426-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20160229860-A1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-11 | — | — | US | disclosed |
| US-20110046108-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007049803-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-05-03 | — | — | WO | disclosed |